Original Article
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis: Subgroup analysis of Latin American patients in the phase 3 randomized UNCOVER-3 study
Comparación de ixekizumab y etanercept o placebo en la psoriasis de moderada a grave: análisis del subgrupo de pacientes latinoamericanos de la fase 3 del estudio aleatorizado UNCOVER-3
F. Valenzuelaa, C. de la Cruz Fernandezb, R.L. Galimbertic, S. Gürbüzd, M. McKean-Matthewse, L. Goncalvesf,
, R. Romitig
a Departamento de Dermatología, Facultad de Medicina Universidad de Chile, Probity Medical Research, Santiago, Chile
b Clinica Dermacross, Santiago, Chile
c Universidad de Buenos Aires Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
d Eli Lilly and Company, Indianapolis, USA
e inVentiv Health, USA
f Eli Lilly and Company, São Paulo, Brazil
g Department of Dermatology, Hospital das Clínicas de Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Leído
7337
Vecesse ha leído el artículo
3261
Total PDF
4076
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 10 | 115 | 24 | 139 |
| 2025 9 | 158 | 30 | 188 |
| 2025 8 | 69 | 34 | 103 |
| 2025 7 | 148 | 44 | 192 |
| 2025 6 | 146 | 30 | 176 |
| 2025 5 | 117 | 46 | 163 |
| 2025 4 | 101 | 43 | 144 |
| 2025 3 | 80 | 27 | 107 |
| 2025 2 | 105 | 45 | 150 |
| 2025 1 | 54 | 58 | 112 |
| 2024 12 | 55 | 48 | 103 |
| 2024 11 | 65 | 59 | 124 |
| 2024 10 | 68 | 44 | 112 |
| 2024 9 | 46 | 38 | 84 |
| 2024 8 | 56 | 49 | 105 |
| 2024 7 | 52 | 41 | 93 |
| 2024 6 | 60 | 42 | 102 |
| 2024 5 | 57 | 38 | 95 |
| 2024 4 | 60 | 28 | 88 |
| 2024 3 | 56 | 39 | 95 |
| 2024 2 | 47 | 30 | 77 |
| 2024 1 | 44 | 38 | 82 |
| 2023 12 | 46 | 33 | 79 |
| 2023 11 | 67 | 30 | 97 |
| 2023 10 | 43 | 24 | 67 |
| 2023 9 | 57 | 35 | 92 |
| 2023 8 | 44 | 17 | 61 |
| 2023 7 | 43 | 34 | 77 |
| 2023 6 | 55 | 19 | 74 |
| 2023 5 | 68 | 29 | 97 |
| 2023 4 | 37 | 25 | 62 |
| 2023 3 | 77 | 23 | 100 |
| 2023 2 | 61 | 38 | 99 |
| 2022 1 | 30 | 52 | 82 |
| 2022 12 | 67 | 70 | 137 |
| 2022 11 | 59 | 57 | 116 |
| 2022 10 | 63 | 50 | 113 |
| 2022 9 | 38 | 56 | 94 |
| 2022 8 | 51 | 77 | 128 |
| 2022 7 | 33 | 53 | 86 |
| 2022 6 | 32 | 40 | 72 |
| 2022 5 | 49 | 43 | 92 |
| 2022 4 | 39 | 32 | 71 |
| 2022 3 | 42 | 47 | 89 |
| 2022 2 | 51 | 37 | 88 |
| 2021 1 | 49 | 52 | 101 |
| 2021 12 | 34 | 46 | 80 |
| 2021 11 | 42 | 47 | 89 |
| 2021 10 | 49 | 60 | 109 |
| 2021 9 | 43 | 39 | 82 |
| 2021 8 | 80 | 55 | 135 |
| 2021 7 | 36 | 44 | 80 |
| 2021 6 | 33 | 56 | 89 |
| 2021 5 | 44 | 54 | 98 |
| 2021 4 | 79 | 99 | 178 |
| 2021 3 | 65 | 52 | 117 |
| 2021 2 | 70 | 34 | 104 |
| 2020 1 | 48 | 24 | 72 |
| 2020 12 | 37 | 22 | 59 |
| 2020 11 | 28 | 37 | 65 |
| 2020 10 | 33 | 19 | 52 |
| 2020 9 | 42 | 27 | 69 |
| 2020 8 | 29 | 35 | 64 |
| 2020 7 | 27 | 27 | 54 |
| 2020 6 | 33 | 44 | 77 |
| 2020 5 | 30 | 27 | 57 |
| 2020 4 | 30 | 17 | 47 |
| 2020 3 | 30 | 19 | 49 |
| 2020 2 | 5 | 0 | 5 |
| 2019 12 | 4 | 0 | 4 |
| 2019 10 | 4 | 0 | 4 |
| 2019 9 | 4 | 0 | 4 |
| 2019 5 | 2 | 0 | 2 |
| 2019 4 | 3 | 0 | 3 |
| 2019 2 | 6 | 2 | 8 |
| 2018 12 | 6 | 0 | 6 |
| 2018 11 | 3 | 2 | 5 |
| 2018 10 | 1 | 0 | 1 |
| 2018 9 | 4 | 0 | 4 |
| 2018 7 | 1 | 0 | 1 |
| 2018 4 | 0 | 2 | 2 |
| 2018 3 | 1 | 0 | 1 |
| 2018 2 | 7 | 5 | 12 |
| 2018 1 | 12 | 7 | 19 |
| 2017 12 | 14 | 11 | 25 |
| 2017 11 | 20 | 12 | 32 |
| 2017 10 | 11 | 16 | 27 |
| 2017 9 | 18 | 27 | 45 |
| 2017 8 | 17 | 60 | 77 |
| 2017 7 | 22 | 245 | 267 |
| 2017 6 | 9 | 20 | 29 |
| 2017 5 | 0 | 30 | 30 |
| 2017 4 | 0 | 67 | 67 |
| 2017 3 | 0 | 23 | 23 |
Mostrar todo
